Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab

Table 3 Examples of genes predictive for response in the discovery but not validation datasets

Gene	N = 210 Discovery Pre-treatment ANOVA t-test	N = 150 Validation Pre-treatment ANOVA t-test
CD28	0.026	0.158
CD80	0.012	0.368
FAIM3	0.008	0.638
FYN	0.006	0.962
IL18BP	0.020	0.958
IL32	0.021	0.686
IL7R	0.009	0.590
INPP4B	0.006	0.740